LA
EW icon

Latitude Advisors’s Edwards Lifesciences EW Stock Holding History

Latitude Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,892
Closed -$340K – 184
2022
Q1 		$340K Buy
2,892
+964
+50% +$108K 0.08% 238
2021
Q4 		$250K Hold
1,928
– – 0.07% 252
2021
Q3 		$218K Buy
+1,928
New +$220K 0.07% 262

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Latitude Advisors's EW Position: Q2 2022 in Review

Latitude Advisors sold out of Edwards Lifesciences (EW) in Q2 2022, closing a stake of 2,892 shares — an estimated $340K sold.

Latitude Advisors first reported a position in EW in Q3 2021 and held it in 3 quarters. The position peaked at $340K in Q1 2022. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

  • Latitude Advisors reported no remaining Edwards Lifesciences position as of Q2 2022 after selling out during the quarter.
  • Latitude Advisors sold 2,892 Edwards Lifesciences shares in Q2 2022, an estimated $340K.
  • Latitude Advisors first reported a position in Edwards Lifesciences in Q3 2021 and held it in 3 quarters.
  • Latitude Advisors's Edwards Lifesciences position peaked at $340K in Q1 2022.
  • 1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on Latitude Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.